Advertisement

Journal of Neurology

, Volume 252, Issue 11, pp 1359–1362 | Cite as

Pre–clinical diagnosis of Alzheimer disease combining platelet amyloid precursor protein ratio and rCBF spect analysis

  • B. BorroniEmail author
  • D. Perani
  • M. Broli
  • F. Colciaghi
  • V. Garibotto
  • B. Paghera
  • C. Agosti
  • R. Giubbini
  • M. Di Luca
  • A. Padovani
ORIGINAL COMMUNICATION

Abstract

Platelet Amyloid Precursor Protein ratio of different abnormal forms and 99mTc–ECD SPECT perfusion analysis were evaluated in Mild Cognitive Impairment (MCI) subjects who progressed to Alzheimer Disease (AD) and in stable MCI. We report that their combined evaluation increases the discriminative power of the analysis in identifying presymptomatic AD. The positive predictive value of these combined markers in identifying progressive MCI was 0.87, and the negative predictive value was 0.90. This observation suggests that the interplay of different markers should be considered for enhancing diagnostic accuracy of pre–clinical AD.

Key words

Alzheimer disease mild cognitive impairment amyloid precursor protein platelets SPECT 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment. Clinical characterization and outcome. Arch Neurol 56:303–308CrossRefPubMedGoogle Scholar
  2. 2.
    Luis CA, Loewenstein DA, Acevedo A, Barker WW, Duara R (2003) Mild cognitive impairment: Directions for future research. Neurology 61:438–444PubMedGoogle Scholar
  3. 3.
    Buerger K, Teipel SJ, Zinkowski R, et al. (2002) CSF tau protein phosphorilated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59:627–629PubMedGoogle Scholar
  4. 4.
    Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A (2002) Cerebrospinal fluid tau and β–amyloid 42 proteins identify Alzheimer disease in subjects with Mild Cognitive Impairment. Arch Neurol 59:1729–1734CrossRefPubMedGoogle Scholar
  5. 5.
    Johnson KA, Jones K, Holman BL, Becker JA, Spiers PA, Satlin A, Albert MS (1998) Preclinical prediction of Alzheimer's disease using SPECT. Neurology 50:1563–1571PubMedGoogle Scholar
  6. 6.
    Borroni B, Colciaghi F, Caltagirone C, Rozzini L, Broglio L, Cattabeni F, Di Luca M, Padovani A (2003) Platelet Amyloid Precursor Protein Abnormalities in mild cognitive impairment predict conversion to dementia of Alzheimer type: a 2–year follow–up study. Arch Neurol 60:1740–1744CrossRefPubMedGoogle Scholar
  7. 7.
    Huang C, Wahlund LO, Almkvist O, Elehu D, Svensson L, Jonsson T, Winblad B, Julin P (2003) Voxel– and VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild cognitive impairment. Neuroimage 19:1137–1144CrossRefPubMedGoogle Scholar
  8. 8.
    Padovani A, Pastorino L, Borroni B, Colciaghi F, Rozzini L, Monastero R, Perez J, Pettinati C, Mussi M, Parinello G, Cottini E, Lenzi GL, Trabucchi M, Cattabeni F, Di Luca M (2001) Amyloid Precursor Protein in Platelets: a peripheral marker for the diagnosis of sporadic AD. Neurology 57:2243–2248PubMedGoogle Scholar
  9. 9.
    Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Haldin C, Pilowsky LS, Pupi A; European Association of Nuclear Medicine (2002) European Association of Nuclear Medicine procedure guidelines for brain perfusion SPET using (99m)Tc–labelled radiopharmaceuticals. Eur J Nucl Mol Imaging 29:BP36–42CrossRefGoogle Scholar
  10. 10.
    Brett M, Anton JL, Valabregue R, Poline JB (2002) Region of interest analysis using an SPM toolbox. NeuroImage 16:abstract N2Google Scholar
  11. 11.
    Okamura N, Arai H, Maruyama M, Higuchi M, Matsui T, Tanji H, Seki T, Hirai H, Chiba H, Itoh M, Sasaki H (2002) Combined analysis of CSF Tau levels and 123I–Iodoamphetamine SPECT in Mild Cognitive Impairment: implications for a novel predictor of Alzheimer's disease. Am J Psychiatry 159:474–476 CrossRefPubMedGoogle Scholar

Copyright information

© Steinkopff-Verlag 2005

Authors and Affiliations

  • B. Borroni
    • 1
    Email author
  • D. Perani
    • 2
  • M. Broli
    • 1
  • F. Colciaghi
    • 5
  • V. Garibotto
    • 3
  • B. Paghera
    • 4
  • C. Agosti
    • 1
  • R. Giubbini
    • 4
  • M. Di Luca
    • 5
  • A. Padovani
    • 1
  1. 1.Clinica NeurologicaUniversità degli Studi di BresciaBresciaItaly
  2. 2.Vita–Salute H San RaffaeleUniversity and Institute of Bioimaging and Molecular Physiology–CNRMilanItaly
  3. 3.University Milano–BicoccaMilanItaly
  4. 4.Nuclear MedicineUnit Brescia HospitalBresciaItaly
  5. 5.Department of Pharmacological SciencesCenter of Excellence for Neurodegenerative Disorders, University of MilanMilanItaly

Personalised recommendations